Novo Nordisk, type 2 diabetes
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...
Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback